Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis

NCT01796405 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT01796405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01796405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Withdrawn
Start date
Not reported
Completion date
Not reported
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

langerhans cell histiocytosis